Vitamin D Deficiency in Axial Spondyloarthritis is Associated With Higher Disease Activity by Zhao, Sizheng et al.
ORIGINAL ARTICLE
doi: 10.5606/ArchRheumatol.2017.6212
Arch Rheumatol 2017;32(x):i-vii
Vitamin D Deficiency in Axial Spondyloarthritis is 
Associated With Higher Disease Activity
Sizheng ZHAO,1 Daniel THONG,2 Stephen DUFFIELD,1 Nicola GOODSON1
1Department of Musculoskeletal Biology I, University of Liverpool Institute of Ageing and Chronic Disease, Liverpool, United Kingdom
2Department of Medical Education, University of Liverpool, Liverpool, United Kingdom
Received: September 16, 2016  Accepted: October 08, 2016  Published online: March 24, 2017
Correspondence: Nicola Goodson, MD. Department of Musculoskeletal Biology I, University of Liverpool Institute of Ageing and Chronic Disease, L69 3GA Liverpool, 
United Kingdom.   Tel: +44 782 486 05 35   e-mail: ngoodson@liverpool.ac.uk
©2017 Turkish League Against Rheumatism. All rights reserved.
ABSTRACT
Objectives: This study aims to assess whether vitamin D deficiency is associated with increased disease activity and functional impairment in axial 
spondyloarthritis (axSpA), with control for its seasonal variation.
Patients and methods: Serum 25-hydroxyvitamin D [25(OH)D] levels were measured in 235 consecutive axSpA patients (176 males, 59 females; 
mean age 46.3 years; range 18 to 85 years) attending a specialist spondyloarthritis service in the United Kingdom. Disease activity and functional 
status were assessed using Bath Ankylosing Spondylitis indices, C-reactive protein, and erythrocyte sedimentation rates. Vitamin D deficiency was 
defined as 25(OH)D <30 nmol/L. Associations between vitamin D deficiency and: (i) disease activity (Bath Ankylosing Spondylitis Disease Activity 
Index), (ii) spinal pain, (iii) functional impairment (Bath Ankylosing Spondylitis Functional Index), and (iv) inflammatory markers were explored using 
multivariable logistic regression models (adjusted for age, sex, vitamin D supplementation, and seasonal variation).
Results: Median symptom duration was 17 years (inter-quartile range 8.5 to 28.6 years). Median 25(OH)D was 54.5 nmol/L (inter-quartile range 
34 to 77 nmol/L) and 52 patients (22%) were deficient for vitamin D. Increasing Bath Ankylosing Spondylitis Disease Activity Index (adjusted odds 
ratio 1.23; 95% confidence interval 1.06-1.41), spinal pain visual analog scale (adjusted odds ratio 1.21; 95% confidence interval 1.07-1.38), and 
C-reactive protein (adjusted odds ratio 1.02; 95% confidence interval 1.01-1.04) were each significantly associated with 25(OH)D deficiency.
Conclusion: This cross-sectional study demonstrated associations between vitamin D deficiency and both higher disease activity and functional 
impairment in axSpA. Whilst this may reflect reduced ultra-violet exposure in functionally impaired patients, it supports the hypothesis that vitamin 
D may have an immunomodulatory role. Interventional studies are needed to evaluate a potential causal relationship, as optimizing vitamin D may 
be a cost-effective adjunctive intervention to modify disease activity in axSpA.
Keywords: Ankylosing spondylitis; axial spondyloarthritis; serum 25-hydroxyvitamin D; vitamin D deficiency.
In axial spondyloarthritis (axSpA), chronic 
inflammation is associated with accelerated loss 
of bone mineral density and new bone formation.1 
Although there have been developments in 
understanding the role of inflammation on bone 
loss, subsequent abnormal bone remodeling in 
axSpA remains poorly understood.
Vitamin D is important for calcium 
homeostasis and bone health, but also has 
immunomodulatory effects. Many immune cells 
can convert 25-hydroxyvitamin D [25(OH)D] to 
its active metabolite, 1,25-dihydroxyvitamin D 
[1,25(OH)2D], which has been shown to inhibit 
T-helper 17 (Th17) and Th1 cell activity, and 
promote regulatory T-cells and Th2 cells.2
Axial spondyloarthritis is associated with 
reduced serum 25(OH)D levels when compared 
with healthy controls.3 However, it is not clear 
from previous studies whether 25(OH)D levels 
are associated with increased disease activity 
and functional impairment. This is in part due to 
inherent difficulties in studying serum levels, as 
ultraviolet B (UVB) generation of 25(OH)D follows 
seasonal variation.4 Previous cross-sectional 
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studies, exploring disease association with vitamin 
D levels in axSpA, were not adjusted for season 
of testing.3
Given the potential for vitamin D to influence 
both bone metabolism and the immune system, 
it is hypothesized that vitamin D may influence 
axSpA disease activity. Therefore, in this study, 
we aimed to assess whether vitamin D deficiency 
is associated with increased disease activity and 
functional impairment in axSpA, with control for 
its seasonal variation.
PATIENTS AND METHODS
A total of 235 patients (176 males, 59 females; 
mean age 46.3 years; range 18 to 85 years) 
attending a spondyloarthritis service in Aintree 
University Hospital, UK between November 
2011 and November 2015, with a diagnosis 
of axSpA (assessed using modified New York 
criteria for ankylosing spondylitis or Assessment 
of SpondyloArthritis International Society 
Criteria for axSpA),5,6 were consecutively 
recruited for the study. The clinical data were 
collected during routine out-patient assessments. 
Patient characteristics (age, sex, smoking status 
-recorded as ever or never smoking- and body 
mass index) were recorded at the time of 
assessment. In addition, disease variables were 
recorded including symptom duration, duration 
since diagnosis, human leukocyte antigen B27 
(HLA-B27) status if available, and extra-articular 
disease features. Current use of non-steroidal 
anti-inflammatory drugs, tumor necrosis factor 
inhibitors, and any vitamin D supplementation 
were also recorded. Disease activity and 
functional status were assessed using the Bath 
Ankylosing Spondylitis Disease Activity Index 
(BASDAI), spinal pain visual analog scale (spVAS), 
Bath Ankylosing Spondylitis Functional Index 
(BASFI), and the modified Health Assessment 
Questionnaire (HAQ) disability index.7,8 Blood 
samples were taken in the morning on the 
day of assessment for analysis of erythrocyte 
sedimentation rate (ESR), C-reactive protein 
(CRP), and 25(OH)D, which was measured 
by tandem mass spectrometry. The date of 
assessment was recorded.
Vitamin D deficiency was defined as 25(OH)D 
<30 nmol/L.9  The study protocol was approved by 
Aintree University Hospital and the London-Brent 
Research Ethics Committee (15/LO/1519). A 
written informed consent was obtained from each 
patient. The study was conducted in accordance 
with the principles of the Declaration of Helsinki.
Statistical analysis
Statistical analyses were performed using 
Stata 12® (Stata Corp., Texas, USA). Target sample 
size was calculated at 250 based on an estimate of 
vitamin D deficiency prevalence of 20% and using 
BASDAI as the primary outcome variable with four 
additional covariates. Vitamin D deficient patients 
were compared with non-deficient patients using 
Student’s t-test for Gaussian, Mann-Whitney U for 
non-Gaussian, and chi-squared test for categorical 
variables. Univariate logistic regression was used 
to explore the association between vitamin D 
deficiency and (i) BASDAI, (ii) spVAS, (iii) BASFI, 
and (iv) inflammatory markers (CRP and ESR). 
Variables with significant association were then 
entered into multivariable models adjusting 
for age, sex, vitamin D supplementation, and 
seasonal variation. Secondary analyses were also 
performed using increasing tertiles of each marker 
of disease severity. Given that UVB exposure 
(and vitamin D production) is likely to be reduced 
in those with impaired function, sensitivity 
analyses were performed to investigate whether 
stratification by functional impairment influenced 
association between 25(OH)D deficiency and 
disease activity. The median BASFI in the cohort 
was used to stratify the sample into low and high 
functional impairment.
To adjust for seasonal variation in vitamin 
D deficiency, a sine function was generated: 
F(t)=a*cos(2π*t/365-q), where t=day of the year, 
a=amplitude, and horizontal shift q=2π*tmax/365. 
Values for a and tmax were calculated from 
coefficients of a sine term, bsin*sin(2π*t/365), and 
cosine term, bcos*cos(2π*t/365), included in the 
logit regression model of vitamin D deficiency 
and BASDAI, where a=√(bsin2+ßcos2)=1.14 
and tmax=arctan(b sin/bcos)*365/2π=40.3. 
Logit regression with vitamin D deficiency as 
dependent variable and this sine function as 
independent variable give a coefficient of b=1.00 
(95% confidence interval [CI] 0.55-1.45). Detailed 
methodology was described by Stolwijk et al.10
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RESULTS
The cohort was predominantly male (75%) and 
Caucasian (97%) with median symptom duration 
of 17 years (inter-quartile range 8.5 to 28.6 
years) and median duration since diagnosis of 
4.3 years (inter-quartile range 0.8 to 14.9 years). 
Non-steroidal anti-inflammatory drugs were used 
by 163 patients (69%) and 74 (31%) were treated 
with tumor necrosis factor inhibitors. Patient 
demographics and disease characteristics are 
shown in Table 1.
The median 25(OH)D level was 54.5 nmol/L 
(inter-quartile range 34-77 nmol/L). Deficiency 
for vitamin D was found in 47 (20%) patients. 
Vitamin D supplementation was used by 
60 patients (26%). No associations were observed 
between vitamin D supplementation and vitamin 
D deficiency. Patients deficient for vitamin D 
had both shorter median symptom duration 
and duration since diagnosis. Deficient patients 
were more commonly ever-smokers (55% vs. 
41%) although this difference was not statistically 
significant. Median BASDAI (7.2 vs. 5.5), spVAS 
(8 vs. 5), ESR (10 vs. 8 mm/hr), and CRP (5 vs. 
3 mg/L) were all significantly higher in patients 
deficient for vitamin D (Table 1). No differences 
were observed for BASFI or HAQ.
Peripheral joint involvement was reported 
in 26% of patients and 9% had associated 
inflammatory bowel disease. There was a trend 
towards greater proportion with psoriasis in 
the deficient group compared to non-deficient 
(27% vs. 12%).
Univariate logistic regression revealed that 
vitamin D deficiency was associated with BASDAI, 
spVAS, ESR, and CRP, but not BASFI (Table 2). 
Associations remained significant in multivariate 
models for BASDAI (adjusted odds ratio [ORadj] 
1.23; 95% CI, 1.06-1.41), spVAS (ORadj 1.21; 
95% CI, 1.07-1.38), and CRP (ORadj 1.02; 95% 
CI, 1.01-1.04) adjusted for age, sex, vitamin D 
supplementation, and seasonal variation.
Bath Ankylosing Spondylitis Functional Index 
was not associated with vitamin D deficiency. 
The median BASFI score5.9 was used to stratify 
functional impairment into high and low BASFI 
subgroups. Significant association between 
deficiency and increasing BASDAI was present 
in those with high BASFI (ORadj 1.42; 95% CI, T
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1.04-1.94) but no significant association was seen 
in the subgroup with low BASFI (ORadj 0.92; 95% 
CI, 0.70-1.21).
Associations between vitamin D deficiency 
and increasing tertiles of BASDAI and spVAS 
are shown in Table 3. The highest tertile of 
BASDAI had a three-fold increased likelihood 
of vitamin D deficiency (ORadj 3.1; 95% CI, 
1.27-7.55), compared to those in the lowest 
BASDAI subgroup. A greater than four-fold 
increase in likelihood of vitamin D deficiency was 
observed in patients of the highest spVAS tertile 
(ORadj 4.3; 95% CI, 1.61-11.4), compared to the 
spVAS reference group. Analysis for CRP was not 
statistically significant.
DISCUSSION
Vitamin D deficiency was observed in 20% of this 
cohort of axSpA patients, which is similar to that 
described in other axSpA populations.11 This cross-
sectional study has demonstrated a significant 
association between vitamin D deficiency and 
increased disease activity (BASDAI) in axSpA. 
Similar associations were also observed with 
level of spinal pain and inflammatory markers 
but no significant associations were seen with 
level of functional impairment. There was greater 
than three-fold increased likelihood of vitamin 
D deficiency observed in those with the highest 
tertiles of BASDAI and pain after adjustment 
for age, sex, vitamin D supplementation, and 
seasonal variation.
These results complement the findings from 
an earlier systematic literature review which 
identified that serum levels of 25(OH)D in axSpA 
patients were lower than healthy controls.3 Several 
studies included in this review reported inverse 
correlations between 25(OH)D levels and disease 
activity. Studies which failed to demonstrate 
such associations often employed suboptimal 
methodology. Firstly, there is substantial seasonal 
variation in serum 25(OH)D levels which should 
be accommodated for. Studies in the past have 
either neglected this or tried to overcome seasonal 
Table 2. Univariate and multivariable logistic regression models demonstrating associations between vitamin D 
deficiency and markers of disease severity
BASDAI 1.20 1.05, 1.38 0.006 1.23 1.06, 1.41 0.005
Spinal pain visual analogue scale 1.17 1.04, 1.31 0.008 1.21 1.07, 1.38 0.003
BASFI** 1.11 0.98, 1.25 0.096  
Erythrocyte sedimentation rate (mm/hr)** 1.01 1.00, 1.03 0.038 1.01 1.00, 1.03 0.077
C-reactive protein (md/L)** 1.03 1.01, 1.04 0.004 1.02 1.01, 1.04 0.005
CI: Confidence interval; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath Ankylosing Spondylitis Functional Index; * Adjusted for age, 
sex, vitamin D supplementation, and seasonal variation; ** Regression was performed with Bath Ankylosing Spondylitis Functional Index assessment in 229, 
erythrocyte sedimentation rate in 227, and C-reactive protein in 229 participants.
 Univariate Multivariable adjusted* 
 Odds ratio 95% CI p Odds ratio 95% CI p
Table 3. Association between vitamin D deficiency and increasing tertiles of disease activity and 
functional impairment (adjusted for age, sex, vitamin D supplementation, and seasonal variation)
Bath Ankylosing Spondylitis Disease Activity Index 0-3.9 80 Reference group
 4-7.2 79 1.45 0.57, 3.70
 7.3-10 76 3.10 1.27, 7.55
Spinal pain visual analog scale 0-4 95 Reference group
 5-8 92 3.02 1.25, 7.31
 8.5-10 48 4.29 1.61, 11.4
C-reactive protein 0-1 78 Reference group
 2-6 75 1.13 0.46, 2.77
 7-132 76 2.14 0.92, 4.97
ORadj: Adjusted odds ratio; CI: Confidence interval.
 Vitamin D deficiency
 Tertiles n ORadj 95% CI
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variation by sampling patients within a short time 
window. Secondly, many existing publications 
studied 25(OH)D as one of multiple variables in 
the context of bone metabolism in small axSpA 
cohorts, which can lead to both type 1 and 2 
errors.
The strengths of the current study include use 
of sufficient sample size to study the association 
between vitamin D deficiency and BASDAI, 
with adjustment for important confounders. This 
included adjustment for seasonal variation using 
a sine function. In addition, as many of the 
variables, including 25(OH)D, had non-Gaussian 
distributions, it was necessary to use statistical 
techniques that do not require normally distributed 
data or residuals. Deficiency was studied instead 
of absolute 25(OH)D levels as transformation of 
this strongly skewed variable made interpretation 
complex and difficult.
The sample size was not sufficient to draw firm 
conclusions in the function-stratified subgroups. 
However, the finding of a stronger association 
between BASDAI and vitamin D deficiency in the 
group of patients with high functional impairment 
is interesting. This may be more suggestive of 
vitamin D deficiency having an immunomodulating 
effect rather than simply being the result of high 
disease activity causing immobility and thus less 
UVB exposure and reduced 25(OH)D production. 
However, this is speculation and not supported by 
the results from this small sample. BASFI was not 
significantly associated with vitamin D deficiency 
despite its strong correlation with BASDAI/
spVAS.
Serum 25(OH)D is converted into its active 
metabolite 1,25(OH)2D. This classically occurs 
in the kidney but can also be performed by T- 
and B-cells, macrophages and dendritic cells.2 
1,25(OH)2D is difficult to measure given its low 
serum concentration and short half-life. Serum 
1,25(OH)2D may also have less relevance given 
that proposed immune mechanisms are likely 
auto-/paracrine.2 Nuclear vitamin D receptors are 
expressed by most immune cells. 1,25(OH)2D 
binds to vitamin D receptors which function as a 
ligand-activated transcription factor. In addition 
to well-known effects on calcium metabolism, 
these gene products have been reported to reduce 
proinflammatory pathways and promote those 
involved in immune tolerance.2 The pathology 
of axSpA is thought to involve elevated levels of 
IL23 and a subset of IL23-responsive entheseal 
T-cells.12 1,25(OH)2D has been shown to inhibit 
both subunits of interleukin-23 (IL-23).13,14 IL-17 is 
another important cytokine in the IL-23-axis, and 
therapeutic inhibition of IL-17 has shown clinical 
efficacy.15 Treatment with vitamin D receptors 
agonists decreased IL-17 production in mice.14,16
There are many factors associated with active 
axSpA that could result in a vitamin D deficient 
state. These include the presence of subclinical 
bowel inflammation, associated with active axSpA, 
that may impair absorption; although dietary 
contribution to vitamin D status is small.9 Vitamin 
D deficiency has been reported to correlate with 
chronic pain,17 which may contribute to symptoms 
of axSpA and increase patient-reported measures 
of disease activity.
Interestingly, vitamin D deficient patients had 
shorter median symptom duration and duration 
since diagnosis. This may be explained by the 
fact that patients with longer disease duration 
were significantly more likely to be commenced 
on vitamin D supplementation (data not shown). 
However, use of vitamin D supplementation did not 
appear to have an effect on 25(OH)D levels. This 
reinforces the need to distinguish supplementation 
from treatment doses, as the former is unlikely to 
be adequate in treating deficiency.4 Patients in this 
study only received supplementation at the time of 
assessment. Furthermore, vitamin D formulations 
vary in dose and compliance is well-known to be 
poor, especially when combined with calcium.18
Also interesting was the signal that deficient 
patients were more often smokers. This is in line 
with previous studies of smoking and vitamin D.19 
Smoking and consequent systemic inflammation 
may affect vitamin D absorption and metabolism. 
Smoking status may also be a proxy for lower 
socioeconomic class and/or dietary quality.
Presence of psoriasis showed some association 
with vitamin D deficiency. This is consistent with 
other studies demonstrating greater prevalence 
of deficiency and lower serum levels of 25(OH)
D in psoriasis and psoriatic arthritis compared 
with controls.20 Psoriasis is intimately linked 
with UVB and vitamin D both in treatment and 
possibly pathogenesis.20 Further detailed studies 
powered to explore these interesting results are 
required.
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This study has some limitations. Our axSpA 
cohort appears to have a low proportion of 
HLA-B27 positivity. HLA-B27 was not routinely 
tested at this center (note only in 63%), and only 
ordered where clinical diagnosis was unclear 
(i.e. clinically obvious axSpA is likely to also 
be HLA-B27 positive but would not be tested). 
One other limitation of this study was that we 
did not use the more sensitive index Ankylosing 
Spondylitis Disease Activity Score.21 BASDAI is 
an established, reliable and valid disease activity 
measure in axSpA, but has been shown to be 
less sensitive to change in disease activity than 
Ankylosing Spondylitis Disease Activity Score in 
some studies. However, the fact that we were still 
able to detect significant associations between 
25(OH)D and the Bath indices is a strength of 
the study. An association was also observed 
for CRP, giving some biological credence to 
the observation that disease activity is inversely 
associated with 25(OH)D.
In conclusion, these results support the 
hypothesis that vitamin D deficiency has an 
immunomodulatory role in axSpA. However, the 
cross-sectional study design prevents detection of 
a causal relationship and it is not possible to know 
whether increased disease activity or vitamin D 
deficiency occurred first. Understanding whether 
vitamin D deficiency leads to increased disease 
activity in axSpA through immunomodulation 
is a complex problem that warrants further 
study. In addition, osteoporosis and vertebral 
fractures are important issues in axSpA, with 
the former accelerated by associated functional 
impairment.22 Patients with high BASDAI and 
spVAS have over three times the odds of being 
vitamin D deficient. It is therefore important that 
vitamin D deficiency is identified and treated 
in these patients to optimize bone health. 
The hypothesis that vitamin D deficiency may 
also cause more severe disease has clinical 
importance and is an area for future study, as 
targeting disease control by modulating vitamin 
D levels may be an attractive intervention to 
explore in axSpA.
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